|

Trastuzumab and neratinib Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1

Indications

  • Neratini1
  • RCB Classification 1-21
  • Adjuvant Treatment After Trastuzumab1
  • Early-stage Breast Cancer1
  • HER2-positive Breast Cancer1

Other1 trial

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.